Literature DB >> 6345675

Trypanosoma cruzi: description of a highly purified surface antigen defined by human antibodies.

J Scharfstein, M M Rodrigues, C A Alves, W de Souza, J O Previato, L Mendonça-Previato.   

Abstract

A glycoprotein of 25,000 daltons (G25) purified from T. cruzi extracts is recognized by serum antibodies of Chagas' disease patients. These human antibodies were isolated by affinity chromatography and were used to demonstrate that G25 antigenic determinants are i) represented at the parasite surface, and ii) are expressed in all developmental stages of the parasite's life cycle, as well as in several T. cruzi strains. This antigen-antibody system may be useful for the diagnosis of Chagas' disease because antibodies to radiolabeled G25 are found in the serum of 96.5% of 173 chagasic patients from different endemic areas, but are not found in the serum from other individuals. Taken collectively, the data suggest that antibodies to G25 define highly conserved determinants of the species T. cruzi. Moreover, its remarkable immunogenicity to infected humans offers an opportunity to investigate the role of specific immunologic responses in the pathogenicity of Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345675

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Characterization of cellular immune response to chemically defined glycoconjugates from Leishmania mexicana subsp. amazonensis.

Authors:  M M Rodrigues; M T Xavier; L M Previato; M A Barcinski
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

2.  Involvement of sulfates from cruzipain, a major antigen of Trypanosoma cruzi, in the interaction with immunomodulatory molecule Siglec-E.

Authors:  Maximiliano R Ferrero; Anja M Heins; Luciana L Soprano; Diana M Acosta; Mónica I Esteva; Thomas Jacobs; Vilma G Duschak
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

3.  Identification and partial characterization of Trypanosoma cruzi antigens recognized by T cells and immune sera from patients with Chagas' disease.

Authors:  R T Gazzinelli; V M Leme; J R Cancado; G Gazzinelli; J Scharfstein
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

4.  Species-specific monoclonal antibodies for a membrane antigen(s) in all developmental forms of Trypanosoma cruzi.

Authors:  H Tachibana; K Nagakura; Y Kaneda
Journal:  Z Parasitenkd       Date:  1986

5.  Analysis of Trypanosoma cruzi antigens bound by specific antibodies and by antibodies to related trypanosomatids.

Authors:  F G Araujo
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

6.  Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi.

Authors:  G Lalmanach; R Mayer; C Serveau; J Scharfstein; F Gauthier
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

7.  The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is antigenic in human infections.

Authors:  J Martinez; O Campetella; A C Frasch; J J Cazzulo
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Further characterization of Trypanosoma cruzi GP57/51 as the major antigen expressed by differentiating epimastigotes.

Authors:  M C Bonaldo; J Scharfstein; A C Murta; S Goldenberg
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

9.  Characterization of the T-cell proliferative response to a purified glycopeptide antigen (GP-25) present on the Trypanosoma cruzi cell surface.

Authors:  G A dos Reis; M S Maldonado; L Mendonça-Previato; M A Barcinski
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

10.  Characterization of a glycosyl-phosphatidylinositol-anchored membrane protein from Trypanosoma cruzi.

Authors:  C Hernández-Munaín; M A Fernández; A Alcina; M Fresno
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.